Our pipeline

A differentiated portfolio
built for every patient journey

We are developing a portfolio of novel therapeutics targeting metabolic diseases. Substantial unmet needs persist in obesity, particularly in achieving sustained weight loss and in addressing the key underlying pathologies that impact cardiometabolic health outcomes. Alveus aims to address these critical issues, delivering meaningful improvements in patient quality of life and outcomes.

Development pipeline

A differentiated therapeutic portfolio
built for every patient journey

Alveus's pipeline is focused on next-generation metabolic therapies based on validated mechanisms; the lead asset ALV-100 is currently in Phase 2. The company's preclinical amylin pipeline consists of novel peptides, oral small molecules, and other novel formats targeting improved quality of weight loss.

ALV-100 GIPR antagonism + GLP-1R agonism
ALV-200 AMYR3-selective peptide
ALV-300 Dual amylin-calcitonin receptor agonist (DACRA) small molecule
Fourth program Novel amylin agonist modality
Clinical trial

ALV-100 is now enrolling for the Phase 1b weight loss study. Learn more about participation and eligibility.